Studies conducted by Becton Dickinson (NYSE: BDX) found that a chemical present in its Vacutainer blood collection tubes interfered with lead tests made by Magellan Diagnostics.
The FDA first warned consumers in May of 2017 that Magellan’s lead tests may provide inaccurate results when used with blood drawn from the vein and held in BD’s blood collection tubes. Today, the U.S. regulatory watchdog reported that BD uncovered the chemical explanation for why its tubes were linked to false results with Magellan’s LeadCare tests.
Get the full story at our sister site, Drug Delivery Business News.
The post BD finds chemical from blood collection tube interferes with Magellen lead test appeared first on MassDevice.
from MassDevice https://ift.tt/2G3uDhL
Cap comentari:
Publica un comentari a l'entrada